The Frazier Life Sciences team invests in and builds companies developing and commercializing novel therapeutics at all stages, from company formation to publics.


Collective years of investing and operational experience


Portfolio companies


M&A and IPOs


FDA approved drugs since 2010

Selected M&A and IPOs

Acquired by AstraZeneca in 2016
Acquired by Sanofi in 2022
Acquired by Blueprint Medicines in 2021
IPO in 2019 (NASDAQ: PHAT)
IPO in 2020 (NASDAQ: TARS)
Acquired by Sanofi in 2021
Acquired by Pfizer in 2021

Life Sciences News

Frazier Life Sciences Team

Merck Completes Tender Offer to Acquire Imago BioSciences, Inc.

Sierra Oncology

GSK completes acquisition of Sierra Oncology

Frazier Life Sciences Team

Frazier Life Sciences Closes $987 Million Venture Fund to Invest in Companies Developing Novel Biopharmaceuticals

Frazier Life Sciences Team

Frazier Healthcare Partners Closes Oversubscribed $830 Million Life Sciences Public Fund

View All News

The investments presented herein represent certain investments made by Frazier Life Sciences, but not all investments. A complete list of investments is available upon request.